FDAsafety guidance72% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Triple-Negative Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab